Hemera is a clinical stage gene therapy company that was founded with the sole mission of preserving vision using gene therapy as a one-time treatment in our patients with age-related macular degeneration (AMD). As physicians and scientists, we have been frustrated by our inability to provide treatment for our patients with macular degeneration. We embarked on this mission to preserve vision by developing a gene therapy called HMR59. Currently, HMR59 is under FDA clinical trial testing as a one-time treatment for both the dry and wet forms of AMD. HMR59 is injected during a routine office visit with the goal of preserving vision that will endure the life of our patients.